📊 ATNM Key Takeaways
Investment Thesis
Actinium Pharmaceuticals faces severe financial distress with near-total revenue collapse (97.4% YoY decline), massive operating losses (-$29.8M), and negative free cash flow (-$19.3M). Despite maintaining adequate liquidity, the company is burning cash rapidly with no apparent path to profitability, making this a highly distressed biotech with substantial going-concern risk.
ATNM Strengths
- Strong liquidity position with $53.4M cash and 7.96x current ratio provides short-term runway
- Low leverage with 0.07x debt-to-equity ratio limits financial distress from debt obligations
- Minimal capital expenditure needs ($11K) suggest asset-light business model
ATNM Risks
- Revenue essentially eliminated with only $90K in latest period, down 97.4% YoY indicating business collapse
- Massive operating losses of $29.8M and negative FCF of $19.3M indicate unsustainable cash burn with ~2.8 year runway at current burn rate
- Company is pre-revenue or post-revenue failure with -31,052% net margin and -202.7% ROE, showing fundamental business dysfunction
- Zero gross profit and near-total loss of revenue suggests failed commercialization or product withdrawal
Key Metrics to Watch
- Monthly cash burn rate and cash runway to determine going-concern timeline
- Any pipeline advancement announcements or new revenue-generating partnerships
- Quarterly revenue and operating loss trends to assess if decline has stabilized or continuing deterioration
ATNM Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.96x current ratio provides a solid financial cushion.
ATNM Profitability Ratios
ATNM vs Healthcare Sector
How Actinium Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
ATNM Balance Sheet & Liquidity
ATNM 5-Year Financial Trend
5-Year Trend Summary: Actinium Pharmaceuticals, Inc.'s revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-1.83 indicates the company is currently unprofitable.
ATNM Growth Metrics (YoY)
ATNM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $90.0K | -$5.1M | $-0.16 |
| Q3 2023 | $45.0K | -$5.1M | $-0.38 |
| Q2 2023 | $45.0K | -$5.1M | $-0.33 |
| Q1 2023 | $940.0K | -$5.1M | $-0.23 |
| Q3 2022 | $45.0K | -$5.0M | $-0.30 |
| Q2 2022 | $45.0K | -$5.0M | $-0.25 |
| Q1 2022 | $622.0K | -$5.1M | N/A |
| Q3 2021 | $233.0K | -$4.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ATNM Capital Allocation
ATNM SEC Filings
Access official SEC EDGAR filings for Actinium Pharmaceuticals, Inc. (CIK: 0001388320)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATNM
What is the AI rating for ATNM?
Actinium Pharmaceuticals, Inc. (ATNM) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATNM's key strengths?
Strong liquidity position with $53.4M cash and 7.96x current ratio provides short-term runway. Low leverage with 0.07x debt-to-equity ratio limits financial distress from debt obligations.
What are the risks of investing in ATNM?
Revenue essentially eliminated with only $90K in latest period, down 97.4% YoY indicating business collapse. Massive operating losses of $29.8M and negative FCF of $19.3M indicate unsustainable cash burn with ~2.8 year runway at current burn rate.
What is ATNM's revenue and growth?
Actinium Pharmaceuticals, Inc. reported revenue of $90.0K.
Does ATNM pay dividends?
Actinium Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ATNM SEC filings?
Official SEC filings for Actinium Pharmaceuticals, Inc. (CIK: 0001388320) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATNM's EPS?
Actinium Pharmaceuticals, Inc. has a diluted EPS of $-0.90.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.